Bipolar depression: A review of randomised clinical trials

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 1, 2007, Pages 13-21

  Goodnick, Paul J ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CITALOPRAM; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; GABAPENTIN; IMIPRAMINE; INOSITOL; LAMOTRIGINE; LITHIUM; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PLACEBO; PRAMIPEXOLE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROATE SEMISODIUM; VENLAFAXINE; ZIPRASIDONE;

ADD ON THERAPY; ADJUVANT THERAPY; ASTHENIA; BIPOLAR DEPRESSION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DEPRESSION; DIARRHEA; DIZZINESS; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HAMILTON SCALE; HEADACHE; HUMAN; HYPERLIPIDEMIA; HYPOMANIA; INCREASED APPETITE; INSOMNIA; MANIA; MONOTHERAPY; MOTOR ACTIVITY; NAUSEA; ORTHOSTATIC HYPOTENSION; PAIN; POST HOC ANALYSIS; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN DISEASE; SOMNOLENCE; SUICIDE; SYSTOLIC BLOOD PRESSURE; TREMOR; UNITED STATES; WEIGHT GAIN; XEROSTOMIA;

BIPOLAR DISORDER; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 33846055109     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.1.13     Document Type: Review

References (43)

1. GOODWIN FK, JAMISON KR: Manic-Depressive Illness. New York & Oxford, Oxford University Press, 1990.
2. STOKES PE, SHAMOIAN CA, STOLL PM, PATTON MJ: Efficacy of lithium as acute treatment of manic-depressive illness. Lancet (1971) 1:1319-1325.
3. TONDO L, HENNEN J, BALDESSARINI RJ: Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. Acta Psychiatr. Scand. (2001) 104:163-172.
4. GOODWIN FK, FIREMAN B, SIMON GE: Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA (2003) 290:1467-1473.
5. NEMEROFF CB, EVANS DL, GYULAI L et al.: Double-blind, placebo-controlted comparison of imipramine and paroxetine in the treatment of bipolar depression. Am. J. Psychiatry (2001) 158:906-912.
6. POST RM, UHDE TW, ROY-BYRNE PP, JOFFE RT: Antidepressant effects of carbamazepine. Am. J. Psychiatry (1986) 143:29-34.
7. ZHANG ZJ, KANG WH, TAN QR: Adjunctive herbal medicine with carbamazepine for bipolar disorders: a double-blind, randomized, placebo-controlled study. J. Psychiatr. Res. (2005) Epub ahead of print.
8. DAVIS LL, BARTOLUCCI A, PETTY F: Divalproex in the treatment of bipolar depression: a placebo-controlled study. J. Affect. Dis. (2005) 85:259-266.
9. DUNN RT, GILMER W, FLECK J et al.: Divalproex monotherapy for acute bipolar depression: a double-blind, randomized placebo-controlled trial. 159th Annual Meeting American Psychiatric Association. Toronto, Ontario, Canada (20 - 25 May 2006) NR205.
10. SACHS G, ALTSHULER L, KETTER T: Divalproex versus placebo for the treatment of bipolar depression: poster presented at the American College of Neuropsychopharmacology Annual Meeting. Waikoloa, Hawaii (9 - 13 December 2001).
11. CALABRESE JR, BOWDEN CL, SACHS GS, ASCHER JA, MONAGHAN E, RUDD GD: A double-blind, placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J. Clin. Psychiatry (1999) 60:79-88.
12. Data on file, Lamictal, RM2002/00129/00, clinical study report for SCA40910 (2002).
13. Data on file, Lamictal, RM1997/00712/00, study synopsis of SCAA2010 (603) (1999).
14. Data on file, Lamictal RM2004/00533/00, study synopsis of SCA100223 (2006).
15. GEDDES J, NIERENBERG A, BOURNE E et al.: Lamotrigine for acute treatment of bipolar depression: a retrospective pooled analysis of response rates in three trials. 159th Annual Meeting of the American Psychiatric Association. Toronto, Ontario, Canada (20 - 25 May 2006) NR 219.
16. BROWN EB, MCELROY SL, KECK PE Jr et al.: A 7 week double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J. Clin. Psychiatry (2006) 67(7):1025-1033.
17. SCHAFFER A, ZUKER P, LEVITT AJ: Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression. 159th Annual Meeting of the American Psychiatric Association. Toronto, Ontario, Canada (20 - 25 May 2006) NR 283.
18. MCINTYRE RS, MANCINI DA, FULTON KA. Double-blind acute depression study comparing venlafixine XR and lamotrigine when added to a mood stabilizer in the treatment of bipolar depression. Int. J. Neuropsychopharmacol. (2004) 7(Suppl. 1):S154.
19. NIERENBERG AA, OSTACHER MJ, CALABRESE JR et al.: Treatment-resistant bipolar depression. A STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am. J. Psychiatry (2006) 163:210-216.
20. MCINTYRE RS, MANCINI DA, MCCANN SM: Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder. A preliminary single-blind study. Bipolar Disord (2002) 4:207-213.
21. PRINTZ D, FLATER S, STRICKS L: A prospective, open-label study of ziprasidone augmentationj for bipolar I depression. Poster at the 24th Collegium Internationale Neuro-psychopharmacologicum. Paris, France (20 - 24 June 2004).
22. DUNN RT, ZABLOTSKY B, STAN VA: Efficacy of aripiprazole in the treatment of bipolar depression. 159th Annual Meeting of the American Psychiatric Association. Toronto, Ontario, Canada (20 - 25 May 2006) NR 204.
23. SHELTON RC, STAHL SM: Risperidone and paroxetine given singly and in combination for bipolar depression. J. Clin. Psychiatry (2004) 65(12):1715-1719.
24. TOHEN M, VIETA E, CALABRESE J: Effect of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch. Gen. Psychiatry (2003) 60(11):1079-1088.
25. DUNNER DL, BROWN E, ADAMS DH, DEGENHARDT E, TOHEN M, HOUSTON JP: Olanzapine/fluoxerine combination versus lamotrigine in the long-term treatment of bipolar I depression. 159th Annual Meeting of the American Psychiatric Association. Toronto, Ontario, Canada (20 - 25 May 2006) NR189.
26. CALABRESE JR, KECK PE Jr, MACFADDEN W et al.: A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am. J. Psychiatry (2005) 162:1351-1360.
27. THASE ME, MACFADDEN W, WEISLER RH et al.: Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J. Clin. Psychopharmacol. (2006) in press.
28. HIRSCHFELD RM, SUPPES T, VIETA E, CARLSSON A, STENING G, MACFADDEN W: Quetiapine monotherapy is efficacious for depressive episodes in patients with bipolar II disorder. 159th Annual Meeting of the American Psychiatric Association. Toronto, Ontario, Canada (20 - 25 May 2006) NR 227.
29. WEISLER R, ARVEKVIST R, STENING G, MACFADDEN W: Quetiapine monotherapy is efficacious for depressive episodes of bipolar I disorder: Combined results from two double-blind, placebo-controlled studies. 159th Annual Meeting of the American Psychiatric Association. Toronto, Ontario, Canada (20 - 25 May 2006) NR 298.
30. HARDOY MC, GAROFALO A, MELLINO G, TULIGI F, CADEDDU M, CARTA MG: Quetiapine as add-on treatment for bipolar I disorder: efficacy in preventing relapse of depressive episodes. 159th Annual Meeting of the American Psychiatric Association. Toronto, Ontario, Canada (20 - 25 May 2006) NR 226.
31. MATTINGLY G, LLIVICKY H, CANALE J, ANDERSON R: Quetiapine combination for treatment-resistant depression. 159th Annual Meeting of the American Psychiatric Association. Toronto, Ontario, Canada (20 - 25 May 2006) NR250.
32. GHAEMI SN, ROSENQUIST KJ, KO JY, BALDASSANO CF, KONTOS NJ, BALDESSARINI RJ: Antidepressant treatment in bipolar versus unipolar depression. Am. J. Psychiatry (2004) 161:163-165.
33. LEVERICH GS, ALTSHULER LL, FRYE MA et al.: Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafiaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am. J. Psychiatry (2006) 163:232-239.
34. COHN JB, COLLLINS G, ASHBROOK E, WERNICKE JF: A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int. Clin. Psychopharmacol. (1989) 4(4):313-322.
35. AMSTERDAM JD, SHULTS J: Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar Type I and Type II major depression - lack of manic induction. J. Affect. Dis. (2005) 87(1):121-130.
36. SVESTKA J, ZOURKOVA A, SYNEK O: Sertraline versus amitriptyline in the treatment of in-patients with acute depressive disorders. Eur. Neuropsychopharmacol. (2003) 13(Suppl. 4):S236.
37. POST RM, ALTSHULER LL, LEVERICH GS et al.: Higher switch rate on venlafaxine than bupropion or sertraline in bipolar depression. Br. J. Psychiatry (2006) in press.
38. VIETA E, MARTINEZ-ARAN A, GOIKOLEA JM et al.: A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J. Clin. Psychiatry (2002) 63:508-512.
39. BAUER M, ZANINELLI R, MULLER-OERLINHAUSEN B: Paroxetine and amitriptyline augmentation of lithium in the treatment of major depression: a double-blind study. J. Clin. Psychopbarmacol. (1999) 19:164-171.
40. YOUNG LT, JOFFE RT ROBB JC: Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am. J. Psychiatry (2000) 157:124-126.
41. SACHS GS, LAFER B, STOLL AL: A double-blind trial of bupropion versus desipramine for bipolar depression. J. Clin. Psychiatry (1994) 55:391-393.
42. GROSSMAN F, POTTER WZ, BROWN EA: A double-blind study comparing idazoxan and bupropion in bipolar depressed patients. J Affect. Dis. (1999) 56:237-243.
43. CALABRESE JR: Issues in treating bipolar depression. 158th Meeting of American Psychiatric Association. Atlanta, GA (21 - 26 May 2005).